BofA lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Neutral rating on the shares. The firm revised its estimates, updated operating expense and share count and pushed back the REC-617 launch timing, driving its lowered price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Balanced Risk-Reward Keeps Recursion at Hold as Key Clinical Catalysts Remain Longer-Dated
- Unusually active option classes on open February 25th
- Recursion Highlights AI Validation, Extends Cash Runway to 2028
- Recursion Pharmaceuticals reports Q4 EPS (21c), consensus (32c)
- Cathie Wood Invests $3M in CoreWeave Stock Ahead of Earnings and Adds $8.7M in Figma, Trims Exposure in DKNG